This study was not designed or powered to detect a benefit of panitumumab over other standard of care agents in PDAC which would require a large multicentre study given the rarity of KRAS wild-type tumours and well documented challenges in enrolling patients with PDAC onto clinical trials. Here, KRAS is linked to neoplasm.